XSU-T -0.22 SOLQ-T -0.79 SVR-T 0.36 MAL-T 0.28 CHTR-Q 1.95 IDT-N -0.7 FI-N 0.53
Daily Stock Opinions and Ratings
Stockchase Opinions

Robert Floyd Vasogin VAS-T PAST TOP PICK May 14, 2001

(Was a top pick on Aug 29/00 down 15%) Has been up. At an excellent price. Buy.
Robert FloydRobert Floyd
Unknown
Unlock Rating
$9.120

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

DON'T BUY

Vasogin(VAS-T)

Sep 26, 2003
Prefers companies with consistent earnings. Too speculative for them.
Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
No
Unlock Rating
$7.980

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Vasogin(VAS-T)

Nov 20, 2003
Have no earnings and won’t for the next 3 years. Model price is $1.50.
Brian Acker, CABrian Acker, CA
No
Unlock Rating
$6.750

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Vasogin(VAS-T)

Dec 16, 2003
They are risk model on bile tax turned negative a couple of months ago so they sold their holdings. Well-run and has an interesting product. They are in the process of being listed in the US. Wait for some strength in that sector.
David BurrowsDavid Burrows
No
Unlock Rating
$7.470

Stock price when the opinion was issued

biotechnology pharmaceutical
HOLD

Vasogin(VAS-T)

Jan 23, 2004
Have signed on with a bigger company and now have to wait for the revenues and earnings to kick in. Easy money has been made.
Peter HodsonPeter Hodson
No
Unlock Rating
$8.980

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Vasogin(VAS-T)

Mar 24, 2004
Interesting technology.
Ed HoEd Ho
No
Unlock Rating
$7.600

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Vasogin(VAS-T)

Sep 08, 2004
Top Short Doesn't feel they have a lot of R&D to show. Have a lot of cash on the books.
Andrew McCreathAndrew McCreath
No
Unlock Rating
$6.500

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Vasogin(VAS-T)

Jan 07, 2005
Have been building up their balance sheet to complete their final trials. Are now approaching a critical time. Feels the company can start to look better from here.
Robert FloydRobert Floyd
Owned
Unlock Rating
$6.450

Stock price when the opinion was issued

biotechnology pharmaceutical
PAST TOP PICK

Vasogin(VAS-T)

Jan 17, 2005

(Top Short Sept 8/04. Sold in low $5's so he's ahead about 19%.)

Andrew McCreathAndrew McCreath
No
Unlock Rating
$6.160

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Vasogin(VAS-T)

Feb 21, 2007
This one is past the point of no return. Speculative.
Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTA
No
Unlock Rating
$0.430

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Vasogin(VAS-T)

Apr 19, 2007
When a biotech finds the right thing, the stock can jump like crazy. This company just had a 1 for 10 reverse split. 90% of companies that do a reverse split are still down one year later.
Benj GallanderBenj Gallander
No
Unlock Rating
$4.500

Stock price when the opinion was issued

biotechnology pharmaceutical

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

VHI-T -0.15$12.6
AFRM-Q 8.47$88.46
XID-T -0.62$53.17
EMMF-N 0$
UMAX-T -0.13$13.59

Today's Top Picks

XSU-T -0.22$44.85
SOLQ-T -0.79$22.05
SVR-T 0.36$18.91
MAL-T 0.28$15.94
CHTR-Q 1.95$265.58

Popular Articles

Latest Sell Signals

HMAX-T 0.055$14.99
WSM-N 0.13$188.19
CSU-T 128.41$4550.34
COST-Q -1.64$943.32
FICO-N 15.27$1521.64

Most Recent Experts

Mike Philbrick

Mike Philbrick

ReSolve Asset Management

Stockchase Insights

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica